Case Processing Deficiencies
In our last posting we discussed problems in quality management systems found during audits and inspections. In this posting we want to discuss problems seen during inspections regarding the processing of individual case safety reports (ICSRs).
Health agencies, in particular the FDA and the EMA/member states, have detailed requirements on how to process individual case safety reports. This includes SUSARs and serious adverse events (SAEs). In EU, this is detailed in module VI of the Guidelines on Good Pharmacovigilance Practices: Management and Reporting of Adverse Reactions to Medicinal Products. See: https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129135.pdf
In a nutshell the requirements from this Module are:
“Competent authorities and marketing authorisation holders should take appropriate measures in order to collect and collate all reports of suspected adverse reactions associated with medicinal products for human use originating from unsolicited or solicited sources.
For this purpose, a pharmacovigilance system should be developed to allow the acquisition of sufficient information for the scientific evaluation of those reports.
The system should be designed so that it helps to ensure that the collected reports are authentic, legible, accurate, consistent, verifiable and as complete as possible for their clinical assessment.
All notifications that contain pharmacovigilance data should be recorded and archived in compliance with the applicable data protection requirements. The system should also be structured in a way that allows for reports of suspected adverse reactions to be validated in a timely manner and exchanged between competent authorities and marketing authorization holders within the legal reporting time frame.”
In the United States, the Code of Federal Regulations (21CFR314.80 and elsewhere) specifies in less detail the requirements for clinical trial and post marketing serious adverse experiences.
“Each applicant…shall promptly review all adverse drug experience information obtained or otherwise received by the applicant from any source, foreign or domestic, including information derived from commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological/surveillance studies, reports in the scientific literature, and unpublished scientific papers… shall also develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to FDA.
The applicant shall report each adverse drug experience that is both serious and unexpected, whether foreign or domestic, as soon as possible but in no case later than 15 calendar days of initial receipt of the information by the applicant.
The applicant shall promptly investigate all adverse drug experiences that are the subject of these postmarketing 15-day Alert reports and shall submit follow-up reports within 15 calendar days of receipt of new information or as requested by FDA. If additional information is not obtainable, records should be maintained of the unsuccessful steps taken to seek additional information.”
During a governmental or third party inspection the timeliness of reporting of expedited reports is one of the most common areas that inspectors examine. That is, the inspectors will request a listing of on-time and late expedited reports submitted to them. Usually the inspector will walk in with a list of such late reports and will ask to see the list maintained by the company in order to compare them – they had better agree. Thus, it is critically important for the company to track expedited reporting to the FDA, EMA and all other health authorities that must receive such reports. This listing will be one of the first things that the inspector will request during an audit. If the company does not routinely track such listings they will then have to create a listing ad hoc. If the company is not rapidly able to produce such a list this will likely be cited by the inspectors in their report.
Another routine part of the inspection involves the review of the company’s procedural documents, including work instructions, SOP’s, manuals, guidelines and even unofficial “cheat sheets”. Of course, the company must have procedural documents in place which cover, both at a high level and detailed level, the processing of serious adverse events. These SOPs will be reviewed by the inspectors and two comparisons will be made. The first will be an examination of the procedural documents against the laws and regulations that are in effect to ensure that the company’s procedures comply with these requirements. The second will be an examination of the procedural documents against the actual workflow and case handling done by the drug safety/pharmacovigilance group. The inspectors may actually visit the drug safety department, interview the staff, and follow a case or cases through the process from start to finish. If there are significant deviations or errors in the case processing there will also be a citation by the inspectors. This visit can be quite stressful to the staff processing the cases.
In theory the processing of a serious adverse event should be relatively straightforward. In practice however there are many different kinds of SAEs in both the clinical trial and post marketing areas. In the clinical trial setting, cases may come from individual sites either electronically or by paper, from CROs, from other companies or business partners and elsewhere.
In the post marketing area, cases may come from many sources: medical information, telephone call centers, subsidiaries and business partners, the FDA and other health authorities, healthcare professionals, patients, lawyers, social media, poison control centers and other Internet sources and even lawyers. This means that in practice there will be many variations on the actual procedure(s) covering the handling of serious adverse events. Many one-offs will occur to accommodate the receipt and transmission of cases to governments, CROs, business partners and others both internal and external to the company. Unless there is a mechanism built into the procedural documents allowing for such one-offs and waivers and exceptions, there is a possibility that the inspector will cite deviations from the SOP in the final report. This may be the case even if the cases are properly handled and are reported on time.
Since SAE reporting is such a critical part of drug safety and pharmacovigilance, this will be a major focus of almost all inspections and audits. As a consequence, the company must ensure that this processing is impeccably done. Alas, frequently it is not impeccably done and frequently is, in fact, poorly done.
Although the FDA does not publish data on the findings in their inspections, the UK MHRA does publish such information on their website. See https://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con175416.pdf for the findings during period of April 2011 to March 2012.
The findings can be summarized as follows:
Critical findings: 37% involved reference safety information (labeling, investigator brochures, CCSI etc.) which are used for determination of expectedness amongst other things; 11% spontaneous case processing issues, 5% clinical trial. Thus case processing and related issues covered more than half the critical findings.
Major findings: 19% spontaneous case processing, 12% reference safety information, clinical trial PV 4%. Here over one third of the major citations were for case processing issues.
Minor/Other findings: 13% spontaneous case processing, 7% reference safety information, 3% clinical trial PV, 1% literature searches. Here nearly a quarter of the findings were related to case processing.
In addition, MHRA has a slide presentation that includes examples of findings (https://www.mhra.gov.uk/home/groups/is-insp/documents/websiteresources/con015700.ppt):
- No global PV system resulting in either lack of or late expedited reporting and PSURs containing incomplete safety data.
- Use of inappropriate reference safety document for the determination of expectedness.
- All information about suspected ADRs not accessible…
- Lack of reconciliation: internal (medical information, product quality), external (distributors, manufacturers, licensing partners).
- Lack of follow up.
- Late reporting of expeditable cases.
- Lack of QC check (data entry, expedited reporting decision).
- Inadequacies in the construction of, or process used for, literature searching
From the many audits I have performed, some noteworthy findings include:
- SOPs: Poor quality or lacking in detail forcing the staff to essentially create their own case processing methodology which may vary from person to person or group to group within the company – sometimes even within the same group in the same department on the same floor. A telltale sign of this is “cheat sheets” in case processors’ cubbies. Even worse is when each cheat sheet is different!
- What to do: Obviously careful control and design of procedural documents with the assistance of the people who actually do the work is necessary. The presence of cheat sheets suggests the SOPs are not adequate. Someone should own the SOPs and the SOP process.
- Training: Little or none is done. Essentially “sink or swim” producing inconsistency and poor case handling.
- What to do: Again, obviously, training should be seriously done (not just “read and understood”) and documented by expert trainers before the new procedure is put in place.
- Complex process procedures and lack of tracking of cases: Some companies have multiple, convoluted systems to handle different types of cases (expedited cases, serious non-expeditable cases from the US, serious non-expeditable cases from ex-US, special situations and waiver cases, etc.). The result of this is that very often serious AEs get lost in the shuffle, particularly if the case processing system involves multiple handoffs from specialist to specialist rather than ownership by one specialist for the whole process from A to Z. Most of the major commercial safety databases have metrics and tracking modules allowing for a specialist or manager to track his/her or all cases in process such that none are ever lost.
- What to do: Track all cases (serious & non-serious) so that no case ever gets lost and try to keep processes as simple as feasible. It is usually worth taking the time to set up the portal and tracking modules in the safety database. Although this may be a big investment up front it pays off later when volume increases and tracking becomes harder and harder.
- Poor quality control: Similar cases are coded differently or even incorrectly, important missing information in the MedWatch/CIOMS I/E2B file that is present in the source documents, no second set of eyes checking the cases, lack of medical review of non-serious spontaneous AEs such that some serious AEs are misclassified as non-serious, inconsistent MedDRA coding and more.
- What to do: Quality control must be in place during the process, not just at the end when it may be too late to correct problems in a case. This may require assistance and advice from the compliance and quality groups.
- Labeling: The latest Investigator Brochure or product labeling (SmPC, US PI, CCSI etc.) doesn’t get sent to the drug safety/PV group such that they use out of date labeling for expectedness.
- What to do: Again, obviously, the group that handles labeling updates and the drug safety group MUST have a process guaranteeing that the latest labeling gets to the drug safety/PV group.
- Multiple external safety data exchange agreements: Many companies now have agreements with business partners to send, receive, process or in some way handle all or parts of individual case processing. These agreements are usually customized such that each one is different. For example, data may be sent electronically (E2B) to one company and by paper (fax, email); data may be sent on calendar day 4 or 5 or 10; source documents may or may not be sent and may or may not be adequately redacted to protect privacy; no medical review or double medical review (CRO & sponsor). What this means is that all of these “one-offs” increase the number of possible errors in case processing.
- What to do: This may be impossible to correct for older agreements already in place. All one can hope to do is try to make sure that new ones are kept as simple as possible. Even this may not be feasible when dealing with monolithic, large pharma companies that cannot or will not change their procedures to accommodate multiple small companies that they share products with. The best one can do is to be sure that all such contracts are in place and a procedure is set up for each so that cases don’t get lost.
Bottom line: This is a high risk area of drug safety and PV that must be done correctly all the time. It is “low hanging fruit” for inspectors and errors and problems are usually easily picked up. The company must ensure that it is done correctly.
Tags: drug safety, FDA, Pharmacovigilance